TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 27335049
Drug: Vehicle ointment,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle ointment, applied twice daily for 21 days
Study: 16114089
Drug: Butterbur extract
Normalized name: butterbur extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Butterbur extract (Ze 339; 8 mg total petasine; one tablet thrice‐daily)
Study: 16114089
Drug: Fexofenadine (Telfast
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fexofenadine (Telfast 180; one tablet once‐daily)
Study: 10526824
Drug: Dexmedetomidine 0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine 0.3 ng/ml
Study: 10526824
Drug: Dexmedetomidine 0.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine 0.6 ng/ml
Study: 7726352
Drug: Morphine and
Normalized name: morphine and antispasmodics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine and Bupivacaine
Study: 2247104
Drug: Nystatin (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nystatin (oral and vaginal)
Study: 2247104
Drug: Placebo (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (oral and vaginal)
Study: 6451637
Drug: 0.1 mg/kg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1 mg/kg/day of 13‐cis‐retinoic acid
Study: 6451637
Drug: 0.5 mg/kg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg/kg/day of 13‐cis‐retinoic acid
Study: 6451637
Drug: 1.0 mg/kg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.0 mg/kg/day of 13‐cis‐retinoic acid
Study: 28381530
Drug: 0 g
Normalized name: Co Q-10 Gummies
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0 g protein (control)
Study: 28381530
Drug: 5 g
Normalized name: 15 g/31 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 g protein
Study: 28381530
Drug: 10 g
Normalized name: Co Q-10 Gummies
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 g protein
Study: 28381530
Drug: 15 g
Normalized name: 15 g/31 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 g protein
Study: 11485708
Drug: Fluticasone propionate
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fluticasone propionate (88 mg twice daily)
Study: 9674734
Drug: Unfractionated heparin
Normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Unfractionated heparin (UFH) - continuous i.v. infusion (450 U/kg/24 h, n = 6)
Study: 9674734
Drug: Low molecular
Normalized name: Low molecular weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low molecular weight heparin (LMWH) - enoxaparin, s.c. treatment (1.5 mg/kg, n = 12)
Study: 7988629
Drug: Diltiazem CR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diltiazem CR 120 mg b.i.d. for 4 weeks
Study: 7988629
Drug: Plain diltiazem
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plain diltiazem tablets 60 mg q.i.d. for 4 weeks
Study: 2522147
Drug: Intramuscular route
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular route (IM group)
Study: 2522147
Drug: Intradermal route
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intradermal route (ID group)
Study: 18047764
Drug: Anticonvulsant mood
Normalized name: ANTICONVULSANTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anticonvulsant mood stabilizers (carbamazepine, valproic acid)
Study: 12748244
Drug: 250 mg/d
Normalized name: alpelisib 250 mg/day (200 mg x 1 and 50 mg x 1) ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 mg/d gefitinib
Study: 12748244
Drug: 500 mg/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg/d gefitinib
Study: 10817716
Drug: Gemifloxacin 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemifloxacin 20 mg
Study: 10817716
Drug: Gemifloxacin 40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemifloxacin 40 mg
Study: 10817716
Drug: Gemifloxacin 80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemifloxacin 80 mg
Study: 10817716
Drug: Gemifloxacin 160
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemifloxacin 160 mg
Study: 10817716
Drug: Gemifloxacin 600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemifloxacin 600 mg
Study: 10817716
Drug: Gemifloxacin 800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemifloxacin 800 mg
Study: 2052460
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of aminophylline and doxapram
Study: 7083219
Drug: Activated charcoal
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Activated charcoal (25 g orally at 12, 18, 24, 36, and 48 hours)
Study: 28560383
Drug: Placebo capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsules daily for 3-6 weeks
Study: 23432415
Drug: Netazepide 100
Normalized name: Netazepide
DrugBank: Netazepide (DB12355)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Netazepide 100 mg
Study: 23432415
Drug: Netazepide (various
Approvals — FDA: no, EMA: no, PMDA: no
Description: Netazepide (various doses 5, 10, 25 mg)
Study: 23432415
Drug: Netazepide (various
Approvals — FDA: no, EMA: no, PMDA: no
Description: Netazepide (various doses)
Study: 19111850
Drug: Drug and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug and nutritional supplements trials
Study: 14987305
Drug: Mequitazine 10
Normalized name: mequitazine 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mequitazine 10 mg
Study: 14987305
Drug: Mequitazine 15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mequitazine 15 mg
Study: 14987305
Drug: Dexchlorpheniramine 6
Normalized name: dexchlorpheniramine 6 mg oral tablet, extended release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexchlorpheniramine 6 mg
Study: 9135927
Drug: Miglitol (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Miglitol (50 mg t.i.d., followed by 100 mg t.i.d.)
Study: 9135927
Drug: Glibenclamide (3.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glibenclamide (3.5 mg q.d/b.i.d.)
Study: 7970848
Drug: Ciprofloxacin (0.1,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciprofloxacin (0.1, 0.5, 1.0 micrograms/ml)
Study: 3315645
Drug: 12 weeks
Normalized name: deutetrabenazine
DrugBank: Deutetrabenazine (DB12161)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 12 weeks daily PMR instruction provided in class for academic credit (n = 51)
Study: 28787759
Drug: Indocyanine green
Normalized name: Indocyanine Green
DrugBank: Indocyanine green (DB16024)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Indocyanine green (ICG) fluorescence imaging (FI) at 0.25 mg per kg of patient weight injected intraoperatively after explorative laparotomy before CS.
Study: 22587483
Drug: rosiglitazone (4-8
Approvals — FDA: no, EMA: no, PMDA: no
Description: rosiglitazone (4-8 mg/day)
Study: 30699881
Drug: pioglitazone (15-45
Approvals — FDA: no, EMA: no, PMDA: no
Description: pioglitazone (15-45 mg/day)
Study: 19922492
Drug: Cylindrical implant
Normalized name: Imperata cylindrica root extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cylindrical implant (group A)
Study: 19922492
Drug: Tapered implant
Normalized name: dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Tapered implant (group B)
Study: 17448971
Drug: Iron ferrous
Normalized name: Ferrous Sulfate 325 MG Oral Tablet [IRON FERROUS SULFATE]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron ferrous sulphate (256 mg/day; 80 mg of Fe(2+)), vitamin C (1000 mg/day), and folic acid (5mg/day) during the 30‐45 days preceding surgery (Group 2)
Study: 15519131
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg LEV
Study: 15519131
Drug: 2000 mg
Normalized name: bran 2000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2000 mg LEV
Study: 12054147
Drug: Pamidronate (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pamidronate (60 mg iv weekly for three consecutive doses, followed by one infusion every 3 weeks for a total of 24 infusions)
Study: 27546308
Drug: High-Fe formula
Normalized name: Slow-Fe
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-Fe formula (6.6 mg Fe/d)
Study: 27546308
Drug: Low-Fe formula
Normalized name: Slow-Fe
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-Fe formula (1.3 mg Fe/d)
Study: 27546308
Drug: Fe drops
Normalized name: MaxFE Drops
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fe drops (6.6 mg Fe/d)
Study: 23582414
Drug: Optimal medical
Normalized name: Optima Plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Optimal medical therapy (MED)
Study: 19127917
Drug: Intradermal needle
Normalized name: NEEDLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intradermal needle combined with Tuina therapy
Study: 15014407
Drug: Acetylsalicylic acid
Normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acetylsalicylic acid (aspirin)
Study: 9632034
Drug: Once-daily venlafaxine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-daily venlafaxine (37.5 mg daily, increased up to 225 mg daily)
Study: 9632034
Drug: Twice-daily venlafaxine
Normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Twice-daily venlafaxine (37.5 mg daily, increased up to 225 mg daily)
Study: 7890902
Drug: Interferon-alpha-2a therapy
Normalized name: Interferon alpha-2a
DrugBank: Interferon alfa-2a (DB00034)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon-alpha-2a therapy
Study: 28401595
Drug: Cognitive music
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive music training (12 bi-weekly 70-min sessions)
Study: 28401595
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (12 bi-weekly 45-min sessions of gymnastic activities)
Study: 21616512
Drug: High-dose insulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose insulin therapy (5 mU·kg(‐1)·min(‐1) starting at skin incision)
Study: 21616512
Drug: Standard metabolic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard metabolic care (target glycemia 6.0‐10.0 mmol/L, n = 10)
Study: 18431002
Drug: Experimental group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Experimental group (EG) received four-day-in-a-row treatment with 10 degrees rightward deviating prisms.
Study: 18431002
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (CG) received four-day-in-a-row placebo treatment.
Study: 18431002
Drug: Experimental group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Experimental group (EG) at one month post-treatment.
Study: 18431002
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (CG) at one month post-treatment.
Study: 16918222
Drug: Botulinum toxin
Normalized name: Botulinum toxin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Botulinum toxin A (BTA) injections in ankle flexors, hamstrings, and adductors
Study: 12787037
Drug: 0.1% fluocinolone
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1% fluocinolone acetonide solution (FAS)
Study: 12787037
Drug: Both 0.1%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both 0.1% fluocinolone acetonide solution and in orabase (FAS/FAO)
Study: 3924533
Drug: Aspirin (650
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (650 mg qid) with Misoprostol (25 micrograms qid)
Study: 3924533
Drug: Aspirin (650
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (650 mg qid) with Placebo
Study: 24112149
Drug: Tiotropium bromide
Normalized name: Tiotropium Bromide
DrugBank: Tiotropium (DB01409)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tiotropium bromide (5 µg) via Respimat
Study: 21821304
Drug: 16Gy boost
Normalized name: BOOST
Approvals — FDA: no, EMA: no, PMDA: no
Description: 16Gy boost dose
Study: 21821304
Drug: Nomogram including
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Nomogram including histologic grade, DCIS, tumor diameter, age, tamoxifen, chemotherapy, and boost
Study: 15170905
Drug: Leflunomide in
Normalized name: Product containing leflunomide in oral dose form (medicinal product form)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Leflunomide in combination with methotrexate (MTX)
Study: 15170905
Drug: Leflunomide in
Normalized name: Product containing leflunomide in oral dose form (medicinal product form)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Leflunomide in combination with sulfasalazine
Study: 15170905
Drug: Leflunomide in
Normalized name: Product containing leflunomide in oral dose form (medicinal product form)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Leflunomide in combination with infliximab
Study: 15170905
Drug: Leflunomide in
Normalized name: Product containing leflunomide in oral dose form (medicinal product form)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Leflunomide in combination with adalimumab
Study: 15170905
Drug: Lefunomide in
Normalized name: Leflunomide
DrugBank: Leflunomide (DB01097)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lefunomide in combination with etanercept
Study: 15170905
Drug: Lefunomide in
Normalized name: Leflunomide
DrugBank: Leflunomide (DB01097)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lefunomide in combination with anakinra
Study: 9040911
Drug: Modified obstetrics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified obstetrics curriculum at McGill University (MG)
Study: 8176256
Drug: Terbinafine 250
Normalized name: terbinafine 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terbinafine 250 mg taken each morning for 6 days before cyclosporin doses
Study: 8176256
Drug: Cyclosporin 300
Normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclosporin 300 mg taken alone
Study: 8176256
Drug: Terbinafine 250
Normalized name: terbinafine 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terbinafine 250 mg taken on the seventh day with cyclosporin
Study: 8176256
Drug: Terbinafine 250
Normalized name: terbinafine 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terbinafine 250 mg taken with cyclosporin
Study: 3579464
Drug: Loperamide (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Loperamide (0.5 mg/kg/d)
Study: 30445454
Drug: Brief incubation
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Brief incubation (0.3-1.2 million motile sperm/ml for 3-4 hours)
Study: 30445454
Drug: Standard incubation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard incubation (0.3-1.2 million motile sperm/ml for 20 hours)
Study: 25895588
Drug: Telmisartan 80
Normalized name: telmisartan 80 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telmisartan 80 mg + modified release nifedipine 30 mg
Study: 25154152
Drug: 400 microg
Normalized name: Fentanyl 400 microgram buccal film
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 microg of misoprostol followed by 3 tablets of 200 microg misoprostol
Study: 25154152
Drug: Placebo (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (3 tablets)
Study: 19835463
Drug: Control (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (oral glucose-lowering drugs excluding thiazolidinediones)
Study: 17093249
Drug: Neurostimulation (after
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neurostimulation (after 6 months of active treatment)
Study: 15243006
Drug: Water for
Normalized name: WATER FOR INJECTION
DrugBank: Water (DB09145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Water for injection (inert control)
Study: 12821971
Drug: 1.8 g
Normalized name: Calciquid, 1.8 g/5 mL oral syrup
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.8 g CLA per day (low dosage, LD)
Study: 12821971
Drug: 3.6 g
Normalized name: ALCOHOL 3.6 g EXTRACORPOREAL CLOTH
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3.6 g CLA per day (high dosage, HD)
Study: 1976680
Drug: Sequential use
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential use of unmedicated soap (3 min) followed by 'Hibisol' (4 min)
Study: 12028405
Drug: Lamivudine 150
Normalized name: lamivudine 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lamivudine 150 mg daily for four weeks
Study: 9820260
Drug: Individualized Chinese
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individualized Chinese herbal formulations (n = 38)
Study: 11768276
Drug: Standard Chinese
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard Chinese herbal formulation (n = 43)
Study: 9820260
Drug: Both active
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both active treatment groups (individualized and standard CHM)
Study: 29188483
Drug: Re-irradiation treatment
Normalized name: Re-Covr
Approvals — FDA: no, EMA: no, PMDA: no
Description: Re-irradiation treatment schedules
Study: 26873702
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of BRAF inhibitor dabrafenib and MEK inhibitor trametinib
Study: 26873702
Drug: Monotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monotherapy with dabrafenib (plus placebo)
Study: 24744318
Drug: Double-fortified salt
Approvals — FDA: no, EMA: no, PMDA: no
Description: Double-fortified salt (DFS) with 3.3 mg ferrous fumarate (1.1 mg elemental iron) per kg of iodized salt for 7.5 to 9 months
Study: 24744318
Drug: Control iodized
Normalized name: calcium iodized
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control iodized salt (47 mg/kg potassium iodate) for 7.5 to 9 months
Study: 23677749
Drug: Cognitive rehabilitation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive rehabilitation treatment consisting of 16 one-hour individual sessions of therapist-guided cognitive training over 4 weeks, combining computer exercises and metacognitive training.
Study: 20033244
Drug: Chewable tablet
Normalized name: Chewable Tablet
DrugBank: Bismuth subsalicylate (DB01294)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chewable tablet containing calcium and vitamin D (Calci Chew D(3), Nycomed)
Study: 18256175
Drug: Grazax (ALK‐Abelló)
Normalized name: ALK-4290
DrugBank: ALK-4290 (DB15269)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Grazax (ALK‐Abelló) for sublingual immunotherapy
Study: 18256175
Drug: Intranasal corticosteroids
Normalized name: abiraterone and corticosteroids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal corticosteroids and oral antihistamines
Study: 16527695
Drug: Nitazoxanide tablets
Normalized name: Nitazoxanide Tablets
DrugBank: Nitazoxanide (DB00507)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nitazoxanide tablets (500 mg, twice daily for 3 days)
Study: 16527695
Drug: Nitazoxanide oral
Normalized name: nitazoxanide Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitazoxanide oral suspension (500 mg, twice daily for 3 days)
Study: 16527695
Drug: Placebo (matching
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (matching tablet, twice daily for 3 days)
Study: 8755321
Drug: Oral human
Normalized name: Insulin Human
DrugBank: Insulin human (DB00030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral human recombinant epidermal growth factor (450 mg/day)
Study: 8755321
Drug: Oral human
Normalized name: Insulin Human
DrugBank: Insulin human (DB00030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral human recombinant epidermal growth factor (600 mg/day)
Study: 1407989
Drug: Levamisole alone
Normalized name: Levamisole
DrugBank: Levamisole (DB00848)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Levamisole alone (150 mg/day for 3 consecutive days)
Study: 1407989
Drug: Levamisole in
Normalized name: doramectin / levamisole Injectable Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levamisole in combination with prednisone (150 mg/day for 3 consecutive days)
Study: 1407989
Drug: Levamisole (alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levamisole (alone or in combination with prednisone)
Study: 28414474
Drug: Abstinence Incentives
Normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Abstinence Incentives plus weekly behavioral parent training (EXP)
Study: 26122834
Drug: pUDK-HGF (4-16
Approvals — FDA: no, EMA: no, PMDA: no
Description: pUDK-HGF (4-16 mg)
Study: 18230858
Drug: Fast ForWord
Normalized name: Fast Freeze
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fast ForWord Language (FFW‐L)
Study: 18230858
Drug: All conditions
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All conditions (FFW‐L, AE, CALI, ILI)
Study: 12949382
Drug: Tea intake
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tea intake (mean daily intake 525 mL)
Study: 12949382
Drug: 4-O-methylgallic acid
Normalized name: o-Salicylsalicylic acid
DrugBank: Salsalate (DB01399)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 4-O-methylgallic acid excretion (biomarker of tea-derived polyphenols)
Study: 6441716
Drug: Oral potassium
Normalized name: Oral Film
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral potassium supplementation during protein-modified fast
Study: 26607845
Drug: Erythropoiesis-stimulating agent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythropoiesis-stimulating agent (ESA; darbepoetin-α) treatment
Study: 26607845
Drug: Both ESA
Normalized name: esafoxolaner
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both ESA treatment and endurance training
Study: 18167048
Drug: Sugar cane
Normalized name: Sugar cane pollen
DrugBank: Sugarcane (DB10906)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sugar cane policosanol 20 mg daily for 8 weeks
Study: 15320669
Drug: Caffeine (7
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine (7 mg.kg(‐1) of body weight)
Study: 15320669
Drug: Placebo (vitamin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (vitamin C, same dosage as caffeine)
Study: 11207403
Drug: 2-min infusion
Normalized name: Interleukin-2/diptheria toxin fusion protein
DrugBank: Denileukin diftitox (DB00004)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 2-min infusion of prochlorperazine (10 mg) followed by a 15-min infusion of saline
Study: 11207403
Drug: 15-min infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 15-min infusion of prochlorperazine (10 mg) following a 2-min infusion of saline
Study: 9308800
Drug: Naltrexone alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naltrexone alone or naltrexone in combination with an anti-oestrogen
Study: 8233386
Drug: Mitomycin 0.2
Normalized name: mitomycin 0.2 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mitomycin 0.2 mg
Study: 8233386
Drug: Mitomycin 0.02
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mitomycin 0.02 mg
Study: 3658353
Drug: Both preparations
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both preparations (2.5% in 32 microliters and 10% in 8 microliters)
Study: 30337343
Drug: Walk by
Normalized name: By Ache
Approvals — FDA: no, EMA: no, PMDA: no
Description: Walk by Faith (WbF) - monthly diet and exercise education sessions